(Q37901053)

25 August 2017

1 reference

title

Metabolic syndrome: nature, therapeutic solutions and options (English)

1 reference

25 August 2017

1 reference

Altan Onat

1

1 reference

PubMed ID

21756201

25 August 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

12

1 reference

25 August 2017

1887-1900

1 reference

Banting lecture 1988. Role of insulin resistance in human disease

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

An urban-rural comparison of the prevalence of the metabolic syndrome in Eastern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Prevalence and trends of a metabolic syndrome phenotype among u.s. Adolescents, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The metabolic syndrome in children and adolescents - an IDF consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle-aged and elderly adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Serum uric acid is a determinant of metabolic syndrome in a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Metabolic syndrome and incident diabetes: current state of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of glycemic load on metabolic risk markers in subjects at increased risk of developing metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The case for low carbohydrate diets in diabetes management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Aging, adiposity, and calorie restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Meta-analysis of wine and beer consumption in relation to vascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Associations of alcohol consumption with blood pressure, lipoproteins, and subclinical inflammation among Turks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of the amount and intensity of exercise on plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The influence of physical activity on abdominal fat: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Associations between cardiorespiratory fitness and C-reactive protein in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women--without associated overall health benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Smoking inhibits visceral fat accumulation in Turkish women: relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance, and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Consumption of omega-3 fatty acids is not associated with a reduction in carotid atherosclerosis: the Genetics of Coronary Artery Disease in Alaska Natives study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

21 January 2018

Niacin and laropiprant

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effects of niacin on glucose control in patients with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

Association of Cigarettes Smoked Daily with Obesity in a General Adult Population*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.585462

10.1517/14656566.2011.585462

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21756201